SCHEMBL2227665

SCHEMBL2227665

COc1ccc(OC)c(Nc2nccc(-c3cn(C(C)C)c4cnccc34)n2)c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 11/20 0.69
MKNK1 Q9BUB5 6/20 0.69
IGF1R P08069 3/20 0.52
DYRK1B Q9Y463 3/20 0.52
DYRK1A Q13627 3/20 0.52
CDK2 P24941 2/20 0.52
DYRK3 O43781 1/20 0.52
CLK1 P49759 1/20 0.52
CLK2 P49760 1/20 0.52
CDK5 Q00535 1/20 0.52
CDK5R1 Q15078 1/20 0.52
DYRK2 Q92630 1/20 0.52
CLK4 Q9HAZ1 1/20 0.52
DYRK4 Q9NR20 1/20 0.52
TTK P33981 1/20 0.45
FLT3 P36888 1/20 0.44
GSK3B P49841 2/20 0.43
NFATC1 O95644 1/20 0.43
EGFR P00533 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2228224 0.91 MKNK2 (0.59) MKNK2MKNK1IGF1RDYRK1BDYRK1A
SCHEMBL12445037 0.90 MKNK2 (0.58) MKNK2MKNK1IGF1RDYRK1BDYRK1A
SCHEMBL2227715 0.90 MKNK2 (0.58) MKNK2MKNK1IGF1RDYRK1BDYRK1A
SCHEMBL2227891 0.90 MKNK2 (0.58) MKNK2MKNK1IGF1RDYRK1BDYRK1A
SCHEMBL2229361 0.88 MKNK2 (0.67) MKNK2MKNK1IGF1RDYRK1BDYRK1A
SCHEMBL2229696 0.88 MKNK2 (0.56) MKNK2MKNK1IGF1RDYRK1BDYRK1A
SCHEMBL12444999 0.87 MKNK2 (0.61) MKNK2MKNK1IGF1RDYRK1BDYRK1A
SCHEMBL2230302 0.87 MKNK1 (0.55) MKNK2MKNK1IGF1RDYRK1BDYRK1A
SCHEMBL2227712 0.87 MKNK1 (0.55) MKNK2MKNK1IGF1RDYRK1BDYRK1A
SCHEMBL2229727 0.87 MKNK1 (0.59) MKNK2MKNK1IGF1RDYRK1BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY GOTO YASUHIRO 2011-07-28 US disclosed
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY GOTO YASUHIRO 2011-07-28 US disclosed
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY GOTO YASUHIRO 2011-07-28 US disclosed
WO-2010042337-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY MERCK SHARP & DOHME CORP. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183975-A1 NOVEL 6-AZAINDOLE AMINOPYRIMIDINE DERIVATIVES HAVING NIK INHIBITORY ACTIVITY BRIX1, REL, CNKSR1 MKNK2 181/4885MKNK1 332/4885IGF1R 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.